Current Hypertension Reports

, Volume 11, Issue 4, pp 283–291 | Cite as

Therapeutic approaches to diastolic dysfunction

  • Rajesh Janardhanan
  • Akshay S. Desai
  • Scott D. Solomon
Article

Abstract

Progressive abnormalities of passive stiffness or active relaxation of the myocardium that impair ventricular filling during diastole may be an important contributor to the development of heart failure in patients with preserved ejection fraction. In this review, we discuss the epidemiology and pathophysiology of diastolic dysfunction and heart failure with preserved ejection fraction, highlighting potential therapeutic approaches and exploring the limited available evidence base for improving clinical outcomes in patients with these challenging entities.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Gaasch WH, Zile MR: Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med 2004, 55:373–394.PubMedCrossRefGoogle Scholar
  2. 2.
    Aurigemma GP, Gaasch WH: Diastolic heart failure. N Engl J Med 2004, 351:1097–1105.PubMedCrossRefGoogle Scholar
  3. 3.
    Redfield MM, Jacobsen SJ, Burnett JC Jr, et al.: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194–202.PubMedCrossRefGoogle Scholar
  4. 4.
    Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002, 105:1387–1393.PubMedCrossRefGoogle Scholar
  5. 5.
    Zile MR, Baicu CF, Gaasch WH: Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004, 350:1953–1959.PubMedCrossRefGoogle Scholar
  6. 6.
    Gaasch WH: Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA 1994, 271:1276–1280.PubMedCrossRefGoogle Scholar
  7. 7.
    Vasan RS, Larson MG, Benjamin EJ, et al.: Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999, 33:1948–1955.PubMedCrossRefGoogle Scholar
  8. 8.
    Bhatia RS, Tu JV, Lee DS, et al.: Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355:260–269.PubMedCrossRefGoogle Scholar
  9. 9.
    How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J 1998, 19:990–1003.Google Scholar
  10. 10.
    Boyer JK, Thanigaraj S, Schechtman KB, et al.: Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004, 93:870–875.PubMedCrossRefGoogle Scholar
  11. 11.
    Aurigemma GP, Gottdiener JS, Shemanski L, et al.: Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 2001, 37:1042–1048.PubMedCrossRefGoogle Scholar
  12. 12.
    Owan TE, Hodge DO, Herges RM, et al.: Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251–259.PubMedCrossRefGoogle Scholar
  13. 13.
    O’Connor CM, Gattis WA, Shaw L, et al.: Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. Am J Cardiol 2000, 86:863–867.PubMedCrossRefGoogle Scholar
  14. 14.
    Brogan WC 3rd, Hillis LD, Flores ED, et al.: The natural history of isolated left ventricular diastolic dysfunction. Am J Med 1992, 92:627–630.PubMedCrossRefGoogle Scholar
  15. 15.
    Hunt SA, Abraham WT, Chin MH, et al.: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154–e235.PubMedCrossRefGoogle Scholar
  16. 16.
    Brucks S, Little WC, Chao T, et al.: Contribution of left ventricular diastolic dysfunction to heart failure regardless of ejection fraction. Am J Cardiol 2005, 95:603–606.PubMedCrossRefGoogle Scholar
  17. 17.
    Wachtell K, Smith G, Gerdts E, et al.: Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint. Am J Cardiol 2000, 85:466–472.PubMedCrossRefGoogle Scholar
  18. 18.
    Ho CY, Sweitzer NK, McDonough B, et al.: Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002, 105:2992–2997.PubMedCrossRefGoogle Scholar
  19. 19.
    Schillaci G, Pasqualini L, Verdecchia P, et al.: Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 2002, 39:2005–2011.PubMedCrossRefGoogle Scholar
  20. 20.
    McLaurin LP, Rolett EL, Grossman W: Impaired left ventricular relaxation during pacing-induced ischemia. Am J Cardiol 1973, 32:751–757.PubMedCrossRefGoogle Scholar
  21. 21.
    Angeja BG, Grossman W: Evaluation and management of diastolic heart failure. Circulation 2003, 107:659–663.PubMedCrossRefGoogle Scholar
  22. 22.
    Cain BS, Meldrum DR, Joo KS, et al.: Human SERCA2a levels correlate inversely with age in senescent human myocardium. J Am Coll Cardiol 1998, 32:458–467.PubMedCrossRefGoogle Scholar
  23. 23.
    Kitzman DW, Little WC, Brubaker PH, et al.: Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002, 288:2144–2150.PubMedCrossRefGoogle Scholar
  24. 24.
    Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 2002, 105:1503–1508.PubMedCrossRefGoogle Scholar
  25. 25.
    Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849–1865.PubMedGoogle Scholar
  26. 26.
    Dahlöf B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003.PubMedCrossRefGoogle Scholar
  27. 27.
    Rapp JA, Gheorghiade M: Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Cardiol Clin 2008, 26:23–40, vi.PubMedCrossRefGoogle Scholar
  28. 28.
    Khan NU, Movahed A: The role of aldosterone and aldosterone-receptor antagonists in heart failure. Rev Cardiovasc Med 2004, 5:71–81.PubMedGoogle Scholar
  29. 29.
    Park JB, Touyz RM, Chen X, et al.: Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. Am J Hypertens 2002, 15:78–84.PubMedCrossRefGoogle Scholar
  30. 30.
    Nagata K, Obata K, Xu J, et al.: Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006, 47:656–664.PubMedCrossRefGoogle Scholar
  31. 31.
    Paulus WJ, Tschope C, Sanderson JE, et al.: How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28:2539–2550.PubMedCrossRefGoogle Scholar
  32. 32.
    Bergstrom A, Andersson B, Edner M, et al.: Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004, 6:453–461.PubMedCrossRefGoogle Scholar
  33. 33.
    Setaro JF, Zaret BL, Schulman DS, et al.: Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990, 66:981–986.PubMedCrossRefGoogle Scholar
  34. 34.
    Flather MD, Shibata MC, Coats AJ, et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005, 26:215–225.PubMedCrossRefGoogle Scholar
  35. 35.
    Borlaug BA, Melenovsky V, Russell SD, et al.: Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006, 114:2138–2147.PubMedCrossRefGoogle Scholar
  36. 36.
    Wachtell K, Bella JN, Rokkedal J, et al.: Change in diastolic left ventricular filling after one year of antihypertensive treatment: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 2002, 105:1071–1076.PubMedCrossRefGoogle Scholar
  37. 37.
    Zusman RM, Christensen DM, Federman EB, et al.: Nifedipine, but not propranolol, improves left ventricular systolic and diastolic function in patients with hypertension. Am J Cardiol 1989, 64:51F–61F.PubMedCrossRefGoogle Scholar
  38. 38.
    Schulman SP, Weiss JL, Becker LC, et al.: The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med 1990, 322:1350–1356.PubMedGoogle Scholar
  39. 39.
    Brooks WW, Bing OH, Robinson KG, et al.: Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 1997, 96:4002–4010.PubMedGoogle Scholar
  40. 40.
    Tang WH, Parameswaran AC, Maroo AP, et al.: Aldosterone receptor antagonists in the medical management of chronic heart failure. Mayo Clin Proc 2005, 80:1623–1630.PubMedCrossRefGoogle Scholar
  41. 41.
    Yamamoto K, Masuyama T, Sakata Y, et al.: Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 2000, 47:274–283.PubMedCrossRefGoogle Scholar
  42. 42.
    Klingbeil AU, Schneider M, Martus P, et al.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115:41–46.PubMedCrossRefGoogle Scholar
  43. 43.
    Cleland JG, Tendera M, Adamus J, et al.: The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 2006, 27:2338–2345.PubMedCrossRefGoogle Scholar
  44. 44.
    Corea L, Cardoni O, Fogari R, et al.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996, 60:341–346.PubMedCrossRefGoogle Scholar
  45. 45.
    Johnston CI: Angiotensin II type 1 receptor blockade: a novel therapeutic concept. Blood Press Suppl 2000, 1:9–13.PubMedCrossRefGoogle Scholar
  46. 46.
    Diez J, Querejeta R, Lopez B, et al.: Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002, 105:2512–2517.PubMedCrossRefGoogle Scholar
  47. 47.
    Devereux RB, Dahlof B, Gerdts E, et al.: Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004, 110:1456–1462.PubMedCrossRefGoogle Scholar
  48. 48.
    Epstein BJ, Anderson S: Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff. Pharmacotherapy 2007, 27:1322–1333.PubMedCrossRefGoogle Scholar
  49. 49.
    Dahlof B, Sever PS, Poulter NR, et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895–906.PubMedCrossRefGoogle Scholar
  50. 50.
    Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777–781.PubMedCrossRefGoogle Scholar
  51. 51.
    Mottram PM, Haluska B, Leano R, et al.: Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004, 110:558–565.PubMedCrossRefGoogle Scholar
  52. 52.
    Kunis R, Greenberg H, Yeoh CB, et al.: Coronary revascularization for recurrent pulmonary edema in elderly patients with ischemic heart disease and preserved ventricular function. N Engl J Med 1985, 313:1207–1210.PubMedCrossRefGoogle Scholar
  53. 53.
    Janardhanan R, Daley WL, Naqvi TZ, et al.: Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension. Am Heart J 2006, 152:246–252.PubMedCrossRefGoogle Scholar
  54. 54.
    Solomon SD, Janardhanan R, Verma A, et al.: Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 2007, 369:2079–2087.PubMedCrossRefGoogle Scholar
  55. 55.
    Massie BM, Carson PE, McMurray JJ, et al.: Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359:2456–2467.PubMedCrossRefGoogle Scholar
  56. 56.
    Yip GW, Wang M, Wang T, et al.: The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008, 94:573–580.PubMedCrossRefGoogle Scholar
  57. 57.
    Little WC, Zile MR, Kitzman DW, et al.: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005, 11:191–195.PubMedCrossRefGoogle Scholar
  58. 58.
    Zile M, Gaasch W, Little W, et al.: A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design. J Card Fail 2004, 10:193–199.PubMedCrossRefGoogle Scholar
  59. 59.
    Lewis GD, Semigran MJ: The emerging role for type 5 phosphodiesterase inhibition in heart failure. Curr Heart Fail Rep 2006, 3:123–128.PubMedCrossRefGoogle Scholar
  60. 60.
    Fukui S, Fukumoto Y, Suzuki J, et al.: Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. J Cardiovasc Pharmacol 2008, 51:317–326.PubMedCrossRefGoogle Scholar
  61. 61.
    Phrommintikul A, Tran L, Kompa A, et al.: Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol 2008, 294:H1804–H1814.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  • Rajesh Janardhanan
  • Akshay S. Desai
  • Scott D. Solomon
    • 1
  1. 1.Cardiovascular DivisionBrigham and Women’s HospitalBostonUSA

Personalised recommendations